Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 5/20 | 0.63 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2702155 | 1.00 | HDAC2 (0.63) | HDAC2SLC22A6HDAC3HDAC1HDAC8 | |
| SCHEMBL63304 | 1.00 | HDAC2 (0.63) | HDAC2SLC22A6HDAC3HDAC1HDAC8 | |
| SCHEMBL2518292 | 1.00 | HDAC2 (0.63) | HDAC2SLC22A6HDAC3HDAC1HDAC8 | |
| SCHEMBL2065563 | 1.00 | HDAC2 (0.63) | HDAC2SLC22A6HDAC3HDAC1HDAC8 | |
| SCHEMBL15195508 | 0.86 | HDAC2 (0.58) | HDAC2SMN1; SMN2FOLH1LMNA | |
| SCHEMBL10315742 | 0.86 | HDAC2 (0.58) | HDAC2SMN1; SMN2FOLH1LMNA | |
| SCHEMBL7969584 | 0.82 | HDAC2 (0.43) | HDAC2HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL18618644 | 0.81 | HDAC2 (0.44) | HDAC2HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL12601342 | 0.79 | HDAC2 (0.63) | HDAC2HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL869683 | 0.79 | HDAC2 (0.63) | HDAC2SLC22A6HDAC3HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264794-A1 | Method for Preparing Largazole Analogs and Uses Thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8217076-B2 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-8148102-B2 | Sequences for FK228 biosynthesis and methods of synthesizing FK228 and FK228 analogs | UWM RESEARCH FOUNDATION, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100261878-A1 | SEQUENCES FOR FK228 BIOSYNTHESIS AND METHODS OF SYNTHESIZING FK228 AND FK228 ANALOGS | UWM RESEARCH FOUNDATION, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100029731-A1 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2008098199-A2 | SEQUENCES FOR FK228 BIOSYNTNESIS AND METHODS OF SYNTHESIZING FK228 AND FK228 ANALOGS | UWM RESEARCH FOUNDATION, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029731-A1 | Method for preparing largazole analogs and uses thereof | CYP51A1, ADPRS, LPXN | HDAC2 362/4885SLC22A6 4465/4885HDAC3 114/4885 |
| US-20100261878-A1 | SEQUENCES FOR FK228 BIOSYNTHESIS AND METHODS OF SYNTHESIZING FK228 AND FK228 ANALOGS | PFAS, PNKP, TREH | HDAC2 2042/4885SLC22A6 2957/4885HDAC3 919/4885 |
| US-20120264794-A1 | Method for Preparing Largazole Analogs and Uses Thereof | CYP51A1, ADPRS, LPXN | HDAC2 362/4885SLC22A6 4465/4885HDAC3 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.